A method for the production of experimental coronary thrombosis in dogs by the injection of thrombin into the anterior descending branch of the left coronary artery is presented. The clot-dissolving properties of trypsin in the form of Tryptar and Enzar were evaluated. The effect of trypsin was also studied in relation to changes in the clotting mechanism of the blood for the purpose of determining tolerated doses. Regardless of amounts of enzyme or time of administration, there was no evidence to indicate prevention of myocardial infarction.
T HIS project was undertaken in an attempt to substantiate the recent work of several investigators searching for a .substance which would dissolve intravascular thrombi. Sherry, Johnson, and Tillett, 1 making use of the fibrinolytic agent occurring normally in blood, administered streptokinase intravenously. This agent activates profibrinolysin to form fibrinolysin and thus causes an increase in the fibrinolytic activity of the blood. They reported complete dissolution of clots in the ear veins of rabbits 23 of 25 times. Innerfield and his associates-gave trypsin intravenously to dogs and rabbits after producing clots, and reported complete fibrinolytic destruction of some of these. They also reported 8 the destruction of thrombi in patients with acute and chronic thrombophlebitis.
Laufman and Roach, 4 in their experiments on the use of intravenous trypsin in experimental pulmonary embolism, found that trypsin administered in almost any dose after the production of pulmonary embolism had no effect upon the emboli. They did find, however, that infusions of trypsin given before emboli were produced, and again afterward, usually prevented persistence of the clots. Taylor and "Wright" 1 found that trypsin infusions in rabbits did not result in the dissolution of artificially produced thrombi, but in many cases produced neerotie lesions in the From the Besearch Department, Millard Fillmore Hospital, Buffalo, X. Y.
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myocardium and the diaphragm, with death resulting from intravascular hemorrhage or actual thrombosis. The present study was undertaken to determine whether intravenously administered trypsin would cause enzymatic destruction of artificially produced thrombi in the coronary arteries of dogs and thus prevent the development of myocardial infarction. The project was divided into three parts : (1) the development of a technic for the production of coronary thrombosis in dogs which would closely simulate that occurring in humans; (2) determination of the dosage of intravenous trypsin that could be tolerated by normal animals, and (3) the evaluation of trypsin in the treatment of experimental coronary thrombosis.
METUOD

Production of Coronary Thrombosis
Materials. Forty-four dogs averaging approximately 20 Kg. in weight were used. Topical bovine thrombin in a solution of 1,000 units/ml, was the clot-producing agent employed. This was prepared in a dry form and contained no preservative. Tryptar aud Enzar° were the enzymes used and differed from each other only in the acid content. Enzar was prepared with hydrochloric and Tryptar with sulfurie acid.
Procedure. The animals were anesthetized with sodium pentobarbital, 30 mg./Kg. injected intravenously. They were then placed on positivepressure breathing and the chest was opened at the sixth left intercostal space. The pericardial *Tryptar and Enzar, Armour Company, Buffered at a pH of 6.7 in 250 ml. of 5 per cent dextrose.
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Circulation Research, Volume VI, May ltii sac was opened and the anterior surface of the heart exposed. The anterior descending branch of the left coronary artery could sometimes be seen at this time, but more often it had to be exposed by separating the overlying cardiac veins. In the dog, this branch of the left coronary artery supplies 30 per cent of the blood to the heart.' A portion of the artery was dissected free following which two sutures were placed beneath the artei-y about 1 cm. apart. Pull-outs of the same material were then introduced through the previously placed ligatui'es. The distal portion of the artery was tied first and then the proximal portion.
Concentrated thrombin solution, from 0.25 to 0.50 ml., was injected into the isolated segment. The thrombus was allowed to develop for a pei'iod of 3 min. At the end of this time the ligatures were removed by means of the pull-outs. The establishment of the thrombosis was verified in each animal by puncturing the site of the thrombus with a needle and observing whether blood leakage occurred on withdrawal of the needle. If it did, additional thrombin was injected after lirst reapplying the ligatures.
Twenty-four dogs in all were operated upon to evaluate the technic. Eight died, and in each case the cause of death was ventricular fibrillation as substantiated by electrocardiograms. This appeared to be seeondaj 1 }' to either severe hemorrhage from the anterior cardiac veins or to excessive manipulation of the heart. The surviving 16 animals were sacrificed 7 days after surgery. Of sixteen surviving animals, 4 had myocardiol fibrosis and 12 had developed myocardial infarction.
In all 12 reversal of the eleetrocardiographic changes was beginning by the end of 7 days ( fig. 1 ). Pathologic findings when these animals were sacrificed included gross evidence of infarction with areas of scarring. Microscopically there were: (1) thrombosis of coronary arteries with myocardial infarction, (2) large areas of necrosis with beginning fibroblastic proliferation, (3) various degrees of inflammatory infiltration with acute fihrinous epicarditis; (4) leukocytic infiltration in areas of necrosis with capillary hemorrhage, and (5) blood produced a lengthening of the clotting time, infinity being reached with 5 mg.
According to Taylor and Wright,' such results mean that trypsin, in small concentration, causes a conversion of prothrombin to thrombin. In higher concentrations, because of its proteolytic destructive action on both prothrombin and fibrinogen, it makes the blood permanently incoagulable. However, preformed clots remained unaffected by trypsin regardless of concentration. These findings confirm the original work done by Eagle and Harris. ' Effect of Trypsin on Blood Clotting Time In Vivo. Trypsin was administered intravenously to 5 normal dogs. All received 50 mg./Kg. In one the trypsin was given in 500 ml. of isotonic saline solution over a period of 6 hours; in the remaining 4 it was given in 250 ml. of saline solution. Two receiving it in a 6-hour period and 2 in a 3-hour period. All enzyme solutions were buffered at a pH of 6.S and prepared immediately prior to infusion. One animal developed pulmonary edema and died; 4 recovered.
The clotting times reached infinity in all animals within 3 hours after the infusion was begun. In the 4 animals that survived, the clotting time had returned to normal within 4 hours after completion of the infusion. Xo evidence of gross hemolysis was observed.
Preinjection fibrinogen levels ranged from 0.5 to 0.8 Gm./lOO ml. of blood. Three hours after beginning the infusion, fibrinogen levels had dropped to 0.07 Gm./lOO ml. Four hours following completion of the infusion, fibrinogen levels in the surviving animals had returned to between 0.3 and 0.6 Gm./lOO ml.
All animals were autopsied. Those surviving were sacrificed in 7 to 10 days. Pathologic find- ings in all included a minimal degree o£ hemorrhagic pulmonary edema, petechiae of the endocardia! lining of the valves of the heart, and minimal hemorrhage of the niesenteric vessels. There was no evidence of intravaacular thrombosis in any. This would indicate that our rate of administration and dose of trypsin had quietly surpassed the danger of dot formation.
EESULTS
In the final phase of the experiment, 15 dogs in whom coronary occlusion had been experimentally induced by the method described above were treated with trypsin. One group was treated with Tryptar, the other with Enzar.
Tryptar Treated. Six dogs were treated with Tryptar buffered at a pH of 6.8. The first 4 received 50 mg./Kg. over a period of 2 hours. All died at the end of this time. The remaining 2 received 30 mg./Kg. over a 6-hour period. Both dogs lived and were sacrificed 7 days postoperatively. The results are shown in table 1. All infusions were begun 4 hours after establishment of the coronary thrombosis.
Enzar Treated. Nine dogs were treated with Enzar following the production of coronary occlusion. The first 3 animals were given 50 mg./Kg. of this product over a period of 2 hours. All recovered but there was no evidence of clot dissolution on either gross or microscopic examination of the heart. The second 3 animals were given 100 mg./Kg. and all died after 1 hour of infusion. No animal exhibited destruction of the thrombus. The remaining '6 dogs were given 100 mg./Kg. over a period of 6 hours. All died at the end of the infusions and examination of the hearts revealed no evidence of fibrinolytic destruction of the thrombi.
All animals were infused at the rate of 10 drops/min. for the first half-hour to avoid anaphylactic reaction, and the rate was then increased to 25 drops/min. for the remainder of the infusion. The results are shown in table 2.
DISCUSSION
Our results with the products available at the present time reveal both the dangers inherent in the use of trypsin intravenously and the absence of thrombolytic activity of this enzyme in experimentally produced coronary thrombosis. Under the conditions and the criterion employed, trypsin failed to prevent the development of myocardial infarction, and death in each case was attributed to profound peripheral circulatory collapse.
The survival rate appeared higher with Enzar than with Tryptar, but whether this finding indicates an absolute or relatively lesser degree of toxieity of Enzar is uncertain.
The short duration of the complete afibrinogenemia, and the destruction of the prothrombin, do not seem to contraindicate the use of trypsin.
It is interesting to note that Innerfield and Angrist 8 claim fibrinolytic effects of trypsin on the basis of decreased fibrin and platelet mass. It is very difficult to evaluate such changes when thrombi are produced in a peripheral vein as small as a marginal ear vessel. The normal contractility of the thrombus might well be mistaken for enzyme digestion.
The reason why Agress' 8 group of animals exhibited no difficulty in tolerating trypsin was no doubt attributable to the 8-day period over which the total amount was administered. One fact worth mentioning in his results, however, was that eleetrocardiographic changes, persisting for 2 hours only, were accepted as criterion for myocardial infarction. These changes could well have been the result of ischemia. We invariably observed the reversal of the eleetrocardiographic pattern when anoxemia was relieved following removal of the ligatures in animals in which we had failed to produce a thrombosis.
If myoeardial infarction develops in 6 to 12 hours, it would seem logical to begin treatment as soon after the onset of the occlusion as possible if one were striving to prevent the effect of prolonged myocardial ischemia.
The therapeutic action of the proteolytic process of enzyme digestion is clearly evident when trypsin is applied topically to infected and necrotic areas of the body. It is hoped that with further purification of such enzymes their use within the vascular system of the individual will be made possible in amounts that may later prove thrombolytie. At the present time however, it does not appear advisable to use trypsin for this purpose nor for its anticoagulant action in preference to less toxic substances such as heparin and Dicumarol.
SUMMARY
A method of producing coronary thrombosis in dogs has been described. Treatment was begun 4 hours after the production of the thrombosis.
Trypsin, as either Tryptar or Enzar, was safely tolerated in doses of 30 to 50 mg./Kg., but in larger doses was found to be too toxic to be used safely in animals with coronary thrombosis, nor did the larger dose produce any evidence of destruction of the thrombus.
In no surviving animal or in those studied on necropsy was there any evidence of proteolytic dissolution of preformed coronary artery thrombi following the use of either Enzar or Tryptar regardless of the period taken for infusion or the amount given. esseva initiate 4 horas post le production del thrombosis.
Trypsina-tanto in le forma de Tryptar como etiam in le forma de Enzar-esseva tolerate salvemente in doses de 30 a 50 mg per kg de peso corporee, sed in doses plus grande illo se monstrava troppo toxic pro esser usate con impunitate in animales con thrombosis coronari. In plus, le doses augmentate non produceva signos de destruction in le thrombos.
Nulle signo de dissolution proteolytic de preformate thrombos del arteria coronavi, occurrente post le uso de Enzar o de Tiyptar, esseva notate in ulle del animales supervivente o in ulle del animales studiate necropticamente, sin reguardo al periodo de temporc usate pro le infusion o al quantitate del t-ouiposito administrate.
